MOHMolina Healthcare, Inc.
Is the price fair?
A demanding price: priced for +15% a year vs +11% a year delivered, at the top of its own P/E range, and rich vs its sector.
Priced for ~15% a year FCF growth. The price demands more than its three-year revenue growth of 11% a year, priced for acceleration.
Expensive vs its own history: P/E 36.4 vs a 19.1 median over 35 quarters (+90% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MOH's price assumes
Today's price asks for 15% free cash flow growth a year; over the last three years Molina Healthcare, Inc. delivered −41%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.4%
Free cash flow yield · Healthcare Plans median 6.5%
- Growth the price implies
- +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; the business has delivered −41% a year over the last three.
- Price / book
- 2.70
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.70
- EV / EBIToperating margin 0.46%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.14
- Free cash flow, trailing twelve months
- $269M
- Market capitalisation
- $11.3B
- 3-year revenue growth
- +11%
- 3-year free cash flow growth
- −41%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $1.40 |
| Its own P/E history, median | $1.91 |
| Its own P/E history, upper quartile | $2.40 |
| 52-week range | $122.65 – $243.02 |
| Today | $196.98 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.